Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia

Imatinib mesylate (Glivec®, Gleevec™, Novartis International AG) and the second generation ABL tyrosine kinase inhibitors have markedly improved the outcome of patients with chronic myeloid leukemia (CML). More patients are receiving treatment with these inhibitors for prolonged periods of time

[1]  S. Fitter,et al.  Long-term imatinib therapy promotes bone formation in CML patients. , 2008, Blood.

[2]  J. Cornish,et al.  Imatinib Promotes Osteoblast Differentiation by Inhibiting PDGFR Signaling and Inhibits Osteoclastogenesis by Both Direct and Stromal Cell‐Dependent Mechanisms , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  C. Schiffer,et al.  BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. , 2007, The New England journal of medicine.

[4]  J. Steegmann,et al.  Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response , 2007, American journal of hematology.

[5]  D. Mellström,et al.  Smoking is associated with lower bone mineral density and reduced cortical thickness in young men. , 2007, The Journal of clinical endocrinology and metabolism.

[6]  I. Reid,et al.  Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. , 2006, The New England journal of medicine.

[7]  H. Deeg,et al.  International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). , 2006, Blood.

[8]  H. Joensuu,et al.  Imatinib and altered bone and mineral metabolism. , 2006, The New England journal of medicine.

[9]  G. Lyritis,et al.  Imatinib and altered bone and mineral metabolism. , 2006, The New England journal of medicine.

[10]  Brian Walters,et al.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.

[11]  Glenn Heller,et al.  Altered bone and mineral metabolism in patients receiving imatinib mesylate. , 2006, The New England journal of medicine.

[12]  Jamal M. Zekri,et al.  Relative Hypocalcaemia and Muscle Cramps in Patients Receiving Imatinib for Gastrointestinal Stromal Tumour , 2006, Sarcoma.

[13]  M. Griesshammer,et al.  Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). , 2005, Blood.

[14]  T. Brümmendorf,et al.  Effects of Imatinib on Normal Hematopoiesis and Immune Activation , 2005, Stem cells.

[15]  A. B. Lyons,et al.  Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. , 2005, Blood.

[16]  F. Cervantes.  Modern management of myelofibrosis , 2005, British Journal of Haematology.

[17]  M. Le Bousse-Kerdilès,et al.  Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Ansell,et al.  Thalidomide treatment in myelofibrosis with myeloid metaplasia , 2002, British journal of haematology.

[19]  S. Rajkumar,et al.  Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. , 2000, Blood.

[20]  G. Barosi,et al.  The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia , 1999, British journal of haematology.

[21]  S. R. Smith,et al.  IDIOPATHIC MYELOFIBROSIS: ANAEMIA MAY RESPOND TO LOW‐DOSE DEXAMETHASONE , 1994, British journal of haematology.